Maze Therapeutics MAZE
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$6.55M (14 inflow days, 6 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 40.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 10.78% to 12.03% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BNP Paribas Financial Markets SNC | Private Company | 2026/Q3 | +542,858 | 1.1% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +243,482 | 2.1% |
| BlackRock | Mutual Fund | 2026/Q3 | +209,829 | 6.8% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,613,857 | 5.0% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +1,140,040 | 2.1% |
| BlackRock | Mutual Fund | 2026/Q3 | +932,416 | 6.3% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +886,028 | 1.7% |
| Farallon Capital Management, L.L.C. | Hedge Fund | 2026/Q3 | +734,814 | 2.0% |
| Logos Global Management, L.P. | Hedge Fund | 2026/Q3 | +700,000 | 3.5% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +603,933 | 1.7% |
| Frazier Life Sciences Management, LP | VC/PE Fund | 2026/Q3 | +465,641 | 9.2% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +411,504 | 3.6% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +360,811 | 1.8% |
| Driehaus Capital Management LLC | Mutual Fund | 2026/Q3 | +318,724 | 1.7% |
| ADAR1 Capital Management, LLC | Hedge Fund | 2026/Q3 | +289,181 | 0.6% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 1 Nov 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $31.05 | 199,866 |
| 28 Oct 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $32.07 | 32,316 |
| 30 Sep 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $27.02 | 234,367 |
| 30 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $26.93 | – |
| 28 Sep 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $27.06 | 32,316 |
| 3 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Automatic Disposition | -9,705 | $26.22 | – |
| 2 Sep 2026 | Jason Coloma | Chief Executive Officer | Open Market Disposition | -22,638 | $27.12 | 268,868 |
| 2 Sep 2026 | Atul Dandekar | Chief Strategy & Business Officer | Open Market Disposition | -6,434 | $27.12 | 32,316 |
| 2 Sep 2026 | Courtney Phillips | General Counsel | Open Market Disposition | -3,993 | $27.12 | 7,007 |
| 2 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Open Market Disposition | -10,295 | $27.12 | 9,705 |
| 1 Sep 2026 | Courtney Phillips | General Counsel | Intent to Sell (Form 144) | -4,144 | $26.54 | – |
| 1 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -10,685 | $26.53 | – |
| 31 Aug 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $26.31 | 291,506 |
| 31 Aug 2026 | Jason Coloma | Chief Executive Officer | Derivative Exercise and Retained | +50,000 | – | 291,506 |
| 31 Aug 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Retained | +12,500 | – | 38,750 |
| 31 Aug 2026 | Courtney Phillips | General Counsel | Derivative Exercise and Retained | +11,000 | – | 11,000 |
| 31 Aug 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $26.36 | 20,000 |
| 31 Aug 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +20,000 | – | 20,000 |
| 27 Aug 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $27.58 | 26,250 |
| 12 Aug 2026 | Paula Johnson | Director | Other Derivative Acquisition | +36,000 | $27.67 | 36,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 6,684,604 | 12.0% | 8.8 |
| 15 Oct 2026 | 7,527,939 | 13.6% | 10.1 |
| 30 Sep 2026 | 6,565,330 | 11.8% | 6.1 |
| 15 Sep 2026 | 5,678,289 | 10.2% | 10.4 |
| 31 Aug 2026 | 5,918,321 | 10.7% | 16.0 |
| 14 Aug 2026 | 5,988,933 | 10.8% | 16.2 |
No comments yet — be the first to weigh in on MAZE.
Sign in to join the discussion.